Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MRT5410 in Adults
NCT05624606Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SP0273 in influenza (6 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events at 30 months, Number of participants with solicited injection site or systemic reactions at 7 days and 6 more. Started Nov 2022; status: completed.
02
Drugs
SP0273
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05624606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624606.